170 related articles for article (PubMed ID: 38794273)
1. The Role of a Cholecystokinin Receptor Antagonist in the Management of Chronic Pancreatitis: A Phase 1 Trial.
Ciofoaia V; Chen W; Tarek BW; Gay M; Shivapurkar N; Smith JP
Pharmaceutics; 2024 Apr; 16(5):. PubMed ID: 38794273
[TBL] [Abstract][Full Text] [Related]
2. Cholecystokinin Receptor Antagonist Therapy Decreases Inflammation and Fibrosis in Chronic Pancreatitis.
Nadella S; Ciofoaia V; Cao H; Kallakury B; Tucker RD; Smith JP
Dig Dis Sci; 2020 May; 65(5):1376-1384. PubMed ID: 31598921
[TBL] [Abstract][Full Text] [Related]
3. Safety and Dosing Study of a Cholecystokinin Receptor Antagonist in Non-alcoholic Steatohepatitis.
Rabiee A; Gay MD; Shivapurkar N; Cao H; Nadella S; Smith CI; Lewis JH; Bansal S; Cheema A; Kwagyan J; Smith JP
Clin Pharmacol Ther; 2022 Dec; 112(6):1271-1279. PubMed ID: 36087237
[TBL] [Abstract][Full Text] [Related]
4. The somatostatin receptor-adenylate cyclase system in rat pancreatic acinar membranes after temporary pancreaticobiliary duct ligation.
Rodríguez-Martín E; Alvaro-Alonso I; Bodega G; Arilla E
Life Sci; 1997; 61(23):2255-69. PubMed ID: 9408049
[TBL] [Abstract][Full Text] [Related]
5. Cholecystokinin receptor antagonist halts progression of pancreatic cancer precursor lesions and fibrosis in mice.
Smith JP; Cooper TK; McGovern CO; Gilius EL; Zhong Q; Liao J; Molinolo AA; Gutkind JS; Matters GL
Pancreas; 2014 Oct; 43(7):1050-9. PubMed ID: 25058882
[TBL] [Abstract][Full Text] [Related]
6. Role of cholecystokinin in pancreatic exocrine response to intraluminal amino acids and fat.
Stubbs RS; Stabile BE
Am J Physiol; 1985 Mar; 248(3 Pt 1):G347-52. PubMed ID: 2858160
[TBL] [Abstract][Full Text] [Related]
7. Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis.
Niederau C; Liddle RA; Ferrell LD; Grendell JH
J Clin Invest; 1986 Oct; 78(4):1056-63. PubMed ID: 2428840
[TBL] [Abstract][Full Text] [Related]
8. The cholecystokinin antagonist proglumide enhances the analgesic efficacy of morphine in humans with chronic benign pain.
McCleane GJ
Anesth Analg; 1998 Nov; 87(5):1117-20. PubMed ID: 9806692
[TBL] [Abstract][Full Text] [Related]
9. Clinical evaluation of oral administration of a cholecystokinin-A receptor antagonist (loxiglumide) to patients with acute, painful attacks of chronic pancreatitis: a multicenter dose-response study in Japan.
Shiratori K; Takeuchi T; Satake K; Matsuno S;
Pancreas; 2002 Jul; 25(1):e1-5. PubMed ID: 12131781
[TBL] [Abstract][Full Text] [Related]
10. Proglumide treatment in bile-induced acute experimental pancreatitis.
Tarpila E; Larsson L; Lilja I; Ihse I
Int J Pancreatol; 1988 Mar; 3(2-3):195-202. PubMed ID: 2452222
[TBL] [Abstract][Full Text] [Related]
11. Loxiglumide. A new proglumide analog with potent cholecystokinin antagonistic activity in the rat pancreas.
Otsuki M; Fujii M; Nakamura T; Okabayashi Y; Tani S; Fujisawa T; Koide M; Baba S
Dig Dis Sci; 1989 Jun; 34(6):857-64. PubMed ID: 2470557
[TBL] [Abstract][Full Text] [Related]
12. [Inhibitory effect of CR 1409 (cholecystokinin antagonist) on pancreatic exocrine secretion in rats].
Shiratori K; Watanabe S; Shimizu K; Moriyoshi Y; Chang JH; Takeuchi T
Nihon Shokakibyo Gakkai Zasshi; 1989 Jan; 86(1):70-6. PubMed ID: 2471850
[TBL] [Abstract][Full Text] [Related]
13. Effects of the cholecystokinin A receptor antagonist loxiglumide on the proliferation and cell cycle time of pancreatic acinar cells in rats.
Kanemitsu D; Sakagami J; Motoyoshi T; Nakajima T; Kataoka K
Pancreas; 2006 Mar; 32(2):190-6. PubMed ID: 16552340
[TBL] [Abstract][Full Text] [Related]
14. Receptor strategies in pancreatitis.
Grendell JH
Yale J Biol Med; 1992; 65(5):431-6; discussion 437-40. PubMed ID: 1340060
[TBL] [Abstract][Full Text] [Related]
15. A phase 1/2 trial to evaluate the pharmacokinetics, safety, and efficacy of NI-03 in patients with chronic pancreatitis: study protocol for a randomized controlled trial on the assessment of camostat treatment in chronic pancreatitis (TACTIC).
Ramsey ML; Nuttall J; Hart PA;
Trials; 2019 Aug; 20(1):501. PubMed ID: 31412955
[TBL] [Abstract][Full Text] [Related]
16. Possible role of cholecystokinin in the development of acute pancreatitis in rats.
Shinya H; Fujimura M
Nihon Geka Hokan; 1989 Jan; 58(1):3-17. PubMed ID: 2802913
[TBL] [Abstract][Full Text] [Related]
17. Effect of the cholecystokinin receptor antagonist loxiglumide on pancreatic exocrine function in rats after acute pancreatitis.
Nakano S; Tachibana I; Otsuki M
Pancreas; 1995 Apr; 10(3):287-94. PubMed ID: 7542770
[TBL] [Abstract][Full Text] [Related]
18. Effect of proglumide, a cholecystokinin receptor antagonist, on caerulein-stimulated pancreatic enzyme secretion and pancreatic polypeptide release in the dog.
Fried M; Beglinger C; Koehler E; Whitehouse I; Varga L; Gyr K
Regul Pept; 1984 Mar; 8(2):117-22. PubMed ID: 6729149
[TBL] [Abstract][Full Text] [Related]
19. The effect of cholecystokinin peptides on ovine duodeno-jejunal slow waves with and without pretreatment with proglumide.
Romański KW
J S Afr Vet Assoc; 2007 Dec; 78(4):209-14. PubMed ID: 18507220
[TBL] [Abstract][Full Text] [Related]
20. Cholecystokinin Receptor Antagonist Improves Efficacy of Chemotherapy in Murine Models of Pancreatic Cancer by Altering the Tumor Microenvironment.
Malchiodi ZX; Cao H; Gay MD; Safronenka A; Bansal S; Tucker RD; Weinberg BA; Cheema A; Shivapurkar N; Smith JP
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
